| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
Purity: ≥98%
Vinflunine (F 12158, BMS 710485) is a new and semi-synthetic analog of the vinca alkaloid vinorelbine that is bi-fluorinated strucuturally. As a mitotic or tubulin inhibitor, it has anticancer, anti-angiogenic, vascular-disrupting and anti-metastatic properties. The major effects of Vinflunine on dynamic instability are a slowing of the microtubule growth rate, an increase in growth duration, and a reduction in shortening duration. The effects of Vinflunine on the readmilling rate is examined by following [3H]GTP incorporation into MAP-rich microtubules, and the IC50 is 0.42 μM.
| ln Vitro |
|
||
|---|---|---|---|
| ln Vivo |
|
||
| Animal Protocol |
|
||
| ADME/Pharmacokinetics |
Absorption, Distribution and Excretion
In cancer patients, vinflunine exhibits linear pharmacokinetic characteristics across the dose range (30 mg/m² to 400 mg/m²). Fecal excretion accounts for 2/3 of the total clearance of vinflunine and its metabolites, with the remaining 1/3 excreted in urine. The terminal volume of distribution is large, at 2422 ± 676 L (approximately 35 L/kg), indicating widespread distribution in tissues. The plasma concentration to whole blood concentration ratio is 0.80 ± 0.12. Based on a population pharmacokinetic analysis of 372 patients, the total blood clearance was 40 L/h. Both inter- and intra-individual variability were low, with coefficients of variation of approximately 25% and 8%, respectively. Metabolites/Metabolic Substances: The main metabolite of vinblastine is cytochrome P450 3A4, but 4-O-deacetylated vinblastine (DVFL) may also be slowly generated by various esterases. DVFL is the major metabolite and the only metabolite that retains pharmacological activity. Biological Half-Life: The average terminal half-life is approximately 40 hours. The half-life of the major metabolite DVFL is approximately 120 hours. |
||
| Toxicity/Toxicokinetics |
Protein Binding
Vinpocetine binds to human plasma proteins at a rate of 67.2 ± 1.1%. It primarily binds to high-density lipoprotein and serum albumin, and does not reach saturation within the range of concentrations observed in patients. Binding to α-1 acid glycoprotein and platelets is negligible (< 5%). |
||
| References | |||
| Additional Infomation |
Pharmacodynamics
The antitumor effect of vinblastine depends on drug concentration and exposure time. Vinblastine exerts its antimitotic effect by inhibiting microtubule assembly (micromolar concentration) and reducing the rate and extent of microtubule growth. In vivo experiments have shown that vinblastine has significant antitumor activity against various human xenograft tumors in mice, including prolonging survival and inhibiting tumor growth. Compared with other vinca alkaloids, vinblastine has a lower potency in inducing drug resistance in vitro. |
| Molecular Formula |
C45H54F2N4O8
|
|
|---|---|---|
| Molecular Weight |
816.93
|
|
| Exact Mass |
816.391
|
|
| CAS # |
162652-95-1
|
|
| Related CAS # |
|
|
| PubChem CID |
10629256
|
|
| Appearance |
Typically exists as solid at room temperature
|
|
| Density |
1.39 g/cm3
|
|
| Index of Refraction |
1.652
|
|
| LogP |
5.019
|
|
| Hydrogen Bond Donor Count |
2
|
|
| Hydrogen Bond Acceptor Count |
13
|
|
| Rotatable Bond Count |
10
|
|
| Heavy Atom Count |
59
|
|
| Complexity |
1720
|
|
| Defined Atom Stereocenter Count |
9
|
|
| SMILES |
CC[C@@]1(C=CCN2CC3)[C@@]2([H])[C@@]3(C(C=C([C@](C4=C5C(C=CC=C6)=C6N4)(CC(C[C@@H](C(F)(F)C)C7)([H])CN7C5)C(OC)=O)C(OC)=C8)=C8N9C)[C@]9([H])[C@](C(OC)=O)(O)[C@@H]1OC(C)=O
|
|
| InChi Key |
NMDYYWFGPIMTKO-HBVLKOHWSA-N
|
|
| InChi Code |
InChI=1S/C45H54F2N4O8/c1-8-42-14-11-16-51-17-15-43(36(42)51)30-19-31(34(56-5)20-33(30)49(4)37(43)45(55,40(54)58-7)38(42)59-25(2)52)44(39(53)57-6)21-26-18-27(41(3,46)47)23-50(22-26)24-29-28-12-9-10-13-32(28)48-35(29)44/h9-14,19-20,26-27,36-38,48,55H,8,15-18,21-24H2,1-7H3/t26-,27-,36+,37-,38-,42-,43-,44+,45+/m1/s1
|
|
| Chemical Name |
methyl (1R,9R,10S,11R,12R,19R)-11-acetyloxy-4-[(12S,14R,16R)-16-(1,1-difluoroethyl)-12-methoxycarbonyl-1,10-diazatetracyclo[12.3.1.03,11.04,9]octadeca-3(11),4,6,8-tetraen-12-yl]-12-ethyl-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2241 mL | 6.1205 mL | 12.2410 mL | |
| 5 mM | 0.2448 mL | 1.2241 mL | 2.4482 mL | |
| 10 mM | 0.1224 mL | 0.6120 mL | 1.2241 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
A Phase II Trial of Vinflunine Chemotherapy in Locally-advanced and Metastatic Carcinoma of the Penis (VinCaP)
CTID: NCT02057913
Phase: Phase 2   Status: Completed
Date: 2020-07-23